Cardiac Failure After Bortezomib Treatment in Lung Cancer Patient
Author Information
Author(s): Jens Voortman, Giaccone Giuseppe
Primary Institution: VU University Medical Center
Hypothesis
Baseline presence of sub clinical cardiomyopathy could have predisposed this patient for a cardiac side effect induced by systemic proteasome inhibition.
Conclusion
The patient experienced severe but reversible cardiac failure after treatment with bortezomib and chemotherapy.
Supporting Evidence
- NT-proBNP levels were elevated, indicating pre-existing cardiac dysfunction.
- The patient's ejection fraction improved from 10-15% to 45% over eight months.
- Cardiac failure was reversible after discontinuation of chemotherapy.
Takeaway
A lung cancer patient had heart problems after taking a new cancer drug, but he got better after stopping the treatment.
Methodology
The patient was treated with bortezomib combined with cisplatin and gemcitabine, and various cardiac assessments were performed.
Potential Biases
Potential bias due to the lack of a control group and reliance on retrospective data.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
53-year-old male with stage IIIB squamous cell carcinoma of the lung.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website